Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: An update
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Neuroinflammation is a significant contributor to Alzheimer's disease (AD). Until now, PET imaging of the translocator protein (TSPO) has been widely used to depict the neuroimmune endophenotype of AD. The aim of this review was to provide an update to the results from 2018 and to advance the characterization of the biological basis of TSPO imaging in AD by re‐examining TSPO function and expression and the methodological aspects of interest. Although the biological basis of the TSPO PET signal is obviously related to microglia and astrocytes in AD, the observed process remains uncertain and might not be directly related to neuroinflammation. Further studies are required to re‐examine the cellular significance underlying a variation in the PET signal in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 2×
“While the cerebellum appears to be spared from AD pathological changes in the earliest stages (Braak & Braak, 1991; Thal et al., 2002), a few neuropathological studies have revealed the presence of amyloid angiopathy and diffuse amyloid plaques in the cerebellar cortex of AD patients with dementia,…”
BackgroundMethodNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 3×
“These results support a stage-dependent model of neuroinflammation with a biphasic change, in accordance with transsectional TSPO PET studies and with neuropathological and mechanistic preclinical data (Leng & Edison, 2021).”
BackgroundResultReactive astrocyte nomenclature, definitions, and future directions
Escartin, C., Galea, E., Lakatos, A., O’Callaghan, J. P., Petzold, G. C., Serrano-Pozo, A., Steinhäuser, C., Volterra, A., Carmignoto, G., Agarwal, A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00783-4 · Cited by 2,513 · cited 1×
“This heterogeneity goes beyond the simplified polarizing scheme of neuroprotective and neuro-toxic functions in AD (Escartin et al., 2021; Murray et al., 2014; Ransohoff, 2016).”
BackgroundA polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
Neural mechanisms of ageing and cognitive decline
Bishop, N. A., Lu, T., & Yankner, B. A. (2010) · Nature · doi:10.1038/nature08983 · Cited by 1,323 · cited 1×
“One major concern in the understanding of microglial and astrocyte function in AD lies in inter-species divergences in terms of genetics, morphology, function, and pharmacology (Arranz & De Strooper, 2019; Bishop et al., 2010; Smith & Dragunow, 2014).”
BackgroundSpatial and temporal heterogeneity of mouse and human microglia at single-cell resolution
Masuda, T., Sankowski, R., Staszewski, O., Böttcher, C., Amann, L., Sagar, Scheiwe, C., Nessler, S., Kunz, P., van Loo, G., et al. (2019) · Nature · doi:10.1038/s41586-019-0924-x · Cited by 1,310
Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease
Kisler, K., Nelson, A. R., Montagne, A., & Zlokovic, B. V. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.48 · Cited by 1,243
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“This issue would be even more problematic in TSPO imaging studies where AD biomarkers are not used (Cagnin et al., 2001; Golla et al., 2015, 2016; Kreisl et al., 2013), as the absence of AD pathophysiology in the brain would certainly impact the immune response.”
Background
Cited by
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
Alzheimer's disease drug development pipeline: 2025
Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., Leisgang‐Osse, A. M., & Cheng, F. (2025) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.70098 · Cited by 190
Metadata
- Authors
- Gouilly, D., Saint‐Aubert, L., Ribeiro, M., Salabert, A., Tauber, C., Péran, P., Arlicot, N., Pariente, J., & Payoux, P.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2022-02-10
- Volume
- 55
- Issue
- 5
- Pages
- 1322-1343
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W4210281487
- Cited by
- 63
- References
- 57
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: An update. https://app.cochat.ai/papers/10.1111/ejn.15613
- The paper
- Gouilly, D., Saint‐Aubert, L., Ribeiro, M., Salabert, A., Tauber, C., Péran, P., Arlicot, N., Pariente, J., & Payoux, P. (2022). Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: An update. European Journal of Neuroscience. https://doi.org/10.1111/ejn.15613
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.